Frank E. Blaney - Concepedia

Author

Frank E. Blaney

Also Known As

Blaney, F., F. BLANEY, F. Blaney, F. E. BLANEY, F. E. Blaney, F.E. Blaney, Frank Blaney, Frank E. Blaney, Frank E. Blaney

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)New Frontier Molecular Discovery (United Kingdom)GlaxoSmithKline (Italy)GlaxoSmithKline (United States)

About

Frank E. Blaney is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	737
2	Natural Sciences	12	12	679
3	Engineering	4	4	127
4	Social Sciences	1	1	42
5	Anesthesia	1	1	17

Frank E. Blaney

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Crystal Structure of Human Cytochrome P450 2D6 Paul Rowland, Frank E. Blaney, Martin G. Smyth, Journal of Biological Chemistry	2005	432
Differences in the Central Nervous System Distribution and Pharmacology of the Mouse 5-Hydroxytryptamine-6 Receptor Compared with Rat and Human Receptors Investigated by Radioligand Binding, Site-Directed Mutagenesis, and Molecular Modeling Warren D. Hirst, Bjarke Abrahamsen, Frank E. Blaney, Molecular Pharmacology	2003	218
Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor Barry S. Orlek, Frank E. Blaney, Frank Brown, Journal of Medicinal Chemistry	1991	204
Definition of the G Protein-Coupled Receptor Transmembrane Bundle Binding Pocket and Calculation of Receptor Similarities for Drug Design David E. Gloriam, Steven M. Foord, Frank E. Blaney, Journal of Medicinal Chemistry Reference SetDrug TargetReceptor SimilaritiesBiochemistryFunctional Selectivity	2009	96
CCR2: Characterization of the Antagonist Binding Site from a Combined Receptor Modeling/Mutagenesis Approach Theo A. Berkhout, Frank E. Blaney, Angela Bridges, Journal of Medicinal Chemistry Crystal StructureAntagonist Binding SiteDrug TargetMolecular BiologyNovel Antagonist Ligands	2003	95
6-Chloro-5-methyl-1-[[2-[(2-methyl-3- pyridyl)oxy]-5-pyridyl]carbamoyl]indoline (SB-242084): The First Selective and Brain Penetrant 5-HT<sub>2C</sub> Receptor Antagonist Steven M. Bromidge, Malcolm Duckworth, Ian T. Forbes, Journal of Medicinal Chemistry Altmetric Attention ScorePharmacotherapyChemical BiologyExperimental PharmacologyPharmaceutical Chemistry	1997	84
1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D<sub>3</sub>Receptor Antagonists Fabrizio Micheli, Giorgio Bonanomi, Frank E. Blaney, Journal of Medicinal Chemistry	2007	83
The Selective 5-HT<sub>1B</sub>Receptor Inverse Agonist 1‘-Methyl-5-[[2‘-methyl-4‘- (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-<i>f</i>]indole-3,4‘-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo Laramie M. Gaster, Frank E. Blaney, Susannah Davies, Journal of Medicinal Chemistry	1998	81
Biarylcarbamoylindolines Are Novel and Selective 5-HT<sub>2C</sub> Receptor Inverse Agonists: Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent Steven M. Bromidge, Steven Dabbs, David T. Davies, Journal of Medicinal Chemistry Potential Antidepressant/anxiolytic AgentPsychotropic MedicationInverse AgonistsPharmacotherapyNew Series	2000	79
Unified Route to the Palmarumycin and Preussomerin Natural Products. Enantioselective Synthesis of (−)-Preussomerin G Anthony G. M. Barrett, Frank E. Blaney, Andrew D. Campbell, The Journal of Organic Chemistry Medicinal ChemistryBiosynthesisBioorganic ChemistryEngineeringBiochemistry	2002	76

Page 1